lifestyle.childcarepartnerships.org

Author: Septerna, Inc.

Septerna to Present at Bank of America Securities Health Care Conference

May 5, 2026
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

April 13, 2026
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

March 9, 2026